PARATEK

Corporate Presentation

H.C. Wainwright Global Life Sciences Conference

Monte Carlo, Monaco

9 April 2018

Safe Harbor Statement

Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The information contained in this presentation is accurate only as of the date hereof. "Paratek" and the Paratek logo are trademarks and service marks of Paratek. All other trademarks, service marks, trade names, logos and brand names identified in this presentation are the property of their respective owners.

Certain statements in this presentation, including responses to questions, contain or may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include, but are not limited to, statements about our strategy, future operations, prospects, plans, objectives of management, availability of data from our clinical studies, potential use of our product candidates, including Omadacycline and Sarecycline, the market acceptance of our product candidates, the strength of, and protection offered by, our intellectual property position, the potential clinical risks and efficacy of, and market opportunities for, our product candidates, the timing and stability of our supply chain, the timing of clinical development of, and regulatory approval for, our product candidates, and the nature and timing of our collaboration agreements with respect to our product candidates. The words "anticipate," "estimate," "expect," "potential," "will," "project" and similar terms and phrases are used to identify forward-looking statements. These statements are based on current information and belief and are not guarantees of future performance. Our ability to predict results, financial or otherwise, or the actual effect of future plans or strategies, is inherently uncertain and actual results may differ from those predicted depending on a variety of factors. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations or whether the forward-looking statements ultimately prove to be correct. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include: delays in clinical trials or unexpected results; the risk that data to date and trends may not be predictive of future results; the failure of collaborators to perform obligations under our collaboration agreements; our failure to obtain regulatory approval for our product candidates; if we obtain regulatory approval for our product candidates, the risk that the terms of such approval may limit how we manufacture and market our product candidates; delays in our supply chain, delays in undertaking or completing clinical trials; our products not gaining the anticipated acceptance in the marketplace or acceptance being delayed; our products not receiving reimbursement from healthcare payors; the effects of competition; our inability to protect our intellectual property and proprietary technology through patents and other means; the need for substantial additional funding to complete the development and commercialization of our product candidates; and the other risks described in the "Risk Factors" section and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2017, and our other filings with the SEC.

PARATEK

Paratek Investment Highlights

Omadacycline: Potential Blockbuster Antibiotic in Both Hospital and Community Settings

Potential Blockbuster Antibiotic	• If Approved, 1st New, Once-daily, Multi-indication, Oral Antibiotic in > 10Yrs • > $9 Billion Potential Addressable Market in U.S.*
Modernized Tetracycline: A Promising Antibiotic Profile	• Positive Ph3 Data in Skin Infections (IV/Oral + Oral only) • Positive Ph3 Data in Community Acquired Bacterial Pneumonia (IV/Oral) • Established Safety Profile in > 1,900 subjects
Clear Registration Path: U.S. FDA and EU EMA	• SPA + QIDP + Fast Track • NDA submitted in Q1 2018; under FDA review
Additional Pipeline Potential	• UTI Ph2 underway • Biodefense opportunity: Tx & prophylaxis in plague and anthrax • Life-cycle opportunities: Lyme Dx, prostatitis, Rickettsial Dx
Capital Efficient Commercial Model	• Significant Value Proposition = Hospitalization Minimization • Hospital Promotion Without Branded Broad-spectrum IV + Oral Competitors
Non-dilutive Funding Options	• Omadacycline: Ex-U.S. Commercial Rights (except China) • Sarecycline: Milestones + U.S. Royalties (Allergan); Ex-U.S. Rights (PRTK)

(*) Paratek estimates based on 2015 AMR data current treatment failure rates and a Zyvox 2015 pricing analogue

PARATEK

Omadacycline: A Modernized Tetracycline

First-in-Class Aminomethylcycline: Restoring Tetracycline Efficacy by Overcoming Resistance

7-Position Modification:
Overcomes Efflux Pump



- **No** known metabolites
- **No** CYP interactions identified
- **No** anticipated monitoring
- **No** dosage modifications or monitoring anticipated in hepatic or renal impairment
- **No** hERG channel effects (TQTc[1] study completed at 3x therapeutic exposures)
- **No** known DDI effects identified
- **Low** propensity to induce *C. diff*[2]

9-Position Modification:
Overcomes Ribosomal Protection

(1) Thorough QTc study
(2) Wilcox ECCMID 2016

PARATEK

Two NDA-Ready Assets

U.S. FDA NDA Approvals Projected in 2018



✓ Positive Efficacy Studies or NDA Filed

* We have entered into a collaboration agreement with Zai Lab (Shanghai) Co., Ltd., for greater China region

PARATEK

Timing of Key Milestones

U.S. FDA NDA Approvals Projected in 2018 for Both Omadacycline and Sarecycline

Omadacycline Events	Timing	Results
ABSSSI Phase 3 data: IV and oral	Q2 2016 ✓	Positive Phase 3 data
UTI Phase 1b data: PK/PD	Q4 2016 ✓	Proof-of-principle
CABP Phase 3 data: IV and oral	Q2 2017 ✓	Positive Phase 3 data
ABSSSI Phase 3 data: Oral-only	Q3 2017 ✓	Positive Phase 3 data
UTI Phase 2 initiation	Q4 2017 ✓	Enrolling
NDA submission	Q1 2018 ✓	Completed
NDA acceptance	Q2 2018 ✓	Accepted
Projected NDA approval	Q4 2018	TBD

Sarecycline Events[1]	Timing	Results
Phase 3 efficacy studies	Q1 2017 ✓	Positive Phase 3 data
NDA (Allergan) submission	Oct 2017 ✓	Accepted
Projected NDA Approval	2H 2018	TBD

1. Allergan licensed U.S. development & commercial rights

PARATEK

PARATEK®

Omadacycline Commercial Opportunity

Potential Blockbuster Antibiotic in Both Hospital and Community Settings

Omadacycline Possesses a Multitude of Differentiated Attributes

No Generic Broad Spectrum IV-Oral Hospital Competitors

Attribute	Omadacycline[4]	Quinolones[1,2,3]	Cephalosporins[1,2,3]	Oxazolidinones[1,2,3]	Glycopeptides[1,2,3]
S. pneumoniae	✓	✓	✓	✓	✓
MDR *E.Coli*[5]	✓	✗	✗	✗	✗
Legionella species	✓	✓	✗	✗	✗
S. aureus (MRSA, MSSA)	✓	✗	✗	✓	✓
Low *C. diff* Incidence	✓	✗	✗	✓	✓
Limited Drug-Drug Interactions	✓	✓	✓	✗	✓
No Major Safety Considerations	✓	Tendon Rupture Neurotoxicity	✓	Serotonin syndrome Thrombocytopenia	Renal Toxicity Ototoxicity
Once Daily IV/Oral Dosing	✓	✓	✗	✗	✗

Sources: 1. JMI surveillance 2010, data on file 2. JMI Surveillance 2015, data on file 3. Product Label 4. Anticipated attributes and or activity based on current data 5. In-vitro data, Paratek data on file.

PARATEK

Physician Antibiotic Treatment Decision Priorities

Omadacycline Offers Simplified Solutions to a Complicated Treatment Decision



Source: Paratek sponsored market research

PARATEK

Antibiotic Use-Limiting IV-only Formulations & Safety Considerations in CABP

Omadacycline: A Convenient Monotherapy Once-Daily Oral-IV Alternative



HOSPITAL

The Omadacycline Patient:

- ***Elevated Resistance Risk***
- ***Polymicrobial Pathogen Risk:***
  - Diabetes, Elderly
- ***Contraindications to Generic Options***
  - ß-lactam allergy
  - Quinolone AE's (tendon rupture, confusion)
  - Recent history of *C. diff*

Sources: 1. Lionel A. Mandell, Richard Wunderink, Antonio Anzueto et al. *Clin Infect Dis* 2007; 44:S27-72

PARATEK

Antibiotic Use-Limiting IV-only Formulations & Safety Considerations in ABSSSI

Omadacycline: A Convenient Monotherapy Once-Daily Oral-IV Alternative



The Omadacycline Patient:

- ***Elevated Resistance Risk***
- ***Polymicrobial Pathogen Risk:***
  - Diabetes, Elderly, IVDU
- ***Contraindications to Generic Options***
  - Renal insufficiency
  - SSRI/MAOI DDI
  - ß-lactam allergy

Sources: 1. Dennis L. Stevens, Alan Bisno, Henry F. Chambers et al. *Clin Infect Dis* First published online June 18, 2014, www.merckmanuals.com/professional/infectious-disease/bacteria-and-antibacterial-drugs/fluoroquinolones; Retrieved 8/2017, www.merckmanuals.com/professional/infectious-disease/bacteria-and-antibacterial-drugs/vancomycin. Retrieved 8/2017, Zyvox (linezolid) package insert. New York: Pfizer Inc; 2017.

PARATEK

Hospital Launch for Omadacycline:

Success Begins with Specialists in Years 1-2 Post-Launch



Source 1. 20% est failures (based on hospital patterns) of first line MRSA treatment

PARATEK

Key Factors Enabling Omadacycline Formulary Endorsement

Multiple Indications with a Bioequivalent[1] IV and Oral Formulation

	Omadacycline	Ceftaroline	Delafloxacin	Tedizolid	Dalbavancin	Oritavancin
Multiple Community Indications at Launch	✓	✓	✗	✗	✗	✗
Once-Daily IV	✓	✗	✗	✓	N/A	N/A
Once-Daily Oral	✓	✗	✗	✓	✗	✗
Broad-Spectrum Bacterial Coverage	✓	✓	✓	✗	✗	✗
No Renal or Hepatic Dosage Modifications	✓	✗	✗	✓	✗	✓
Low C. difficile propensity	✓	✗	✗	✓	✓	✓

Sources: Package Inserts, First Data Bank (1) IV and oral exposures are equivalent.

PARATEK

Focus of Launch Efforts

Awareness & Education Leading to Access & Use

Awareness & Education	+	*Access*	=	*Behavior Change*
• Scientific Exchange • Unbranded Disease State Education Programs • Publications		• HEOR Publications • Payer Discussions • Guidelines		• Trial • Usage • Adoption

PARATEK

Addressable U.S. Hospital Market: ~890K patients $2.6B Opportunity by 2028

Empiric IV to Oral Monotherapy in Patients Who Fail to Respond or Are Intolerant to Generic Option



Key Omadacycline launch attributes

- 1st new monotherapy for CABP in over a decade
- 2 indications at launch
- Once daily dosing
- Both an IV and Oral formulation

Total $2.6B[7] Potential Opportunity

[1] AHA data (2015): Projected to 2028
[2] Of patients never receiving confirmed pathogen and getting potential MRSA coverage, 30%+ switch therapies (i.e., to another empiric therapy)
[3] Primary market research (est 16% of hospitalized CABP patients & 16.5% of community CABP patients are "high-risk" and suspected/confirmed to have a resistant pathogen)
[4] CMS Current Treatment: Gram Negative infections (ID's est ~20% failure rate for fluoroquinolones)
[5] Cost per course based on health outcome analysis, 10 day course of therapy and cost of branded Zyvox therapy as an analogue
[6] Cost per course based on mid point for levofloxacin course in UTI, a 450mg OMC daily dose, and 50% price premium to branded oral Zyvox as an analog
[7] Paratek estimates based on 2015 AHA data current treatment failure rates and a Zyvox 2015 pricing analogue

PARATEK

Omadacycline U.S. Timeline to Launch (January 2019)

MSL Education, Publications, HEOR & Payer Dialogue



PARATEK

Pre-Launch and 1st Year Post-Launch Key Deliverables

Publications, Payer Reviews, Distributors & Patient Assistance Programs in Place

Pre Launch

- Publications:
  - All phase 3 manuscripts in press
  - OMC CID supplement in press
- Health value dossier:
  - Budget Impact Model in press
- Payers:
  - OMC reviewed by major payers
- Distributors:
  - All distributors for both IV and Oral under contract
- PRTK patient assistance program:
  - In place at launch

Post Launch

- 3 months Post-Launch:
  - 33% of covered lives under contract
- 12 months Post-Launch:
  - 66% of covered lives under contract
- 12 months Post-Launch:
  - 50% of target hospital formularies

PARATEK

Omadacycline IP Protection and Market Exclusivity

GAIN Act Ensures 10 Years of Market Exclusivity



PARATEK

Key Financial Information

Key Metrics	12/31/17 balance
Total Cash, Cash Equivalents, and Marketable Securities	$151.7 million
Gross Long-term Debt Obligation	$60.0 million
Basic Shares Outstanding	27,941,015
Stock Options, Restricted Stock Units, and Warrants Outstanding	4,897,977

Funding Projected through late 2019 (1)

(1) Includes $50 million gross proceeds from January 2018 equity offering

PARATEK

PARATEK

Back Up

Most Frequent TEAEs in the OASIS-1, OASIS-2 and OPTIC Studies

Omadacycline Safety and Tolerability Profile Established

Selected TEAS Occurring in ≥2% of Patients Receiving Omadacycline in the Pooled Phase 3 CABP and ABSSSI Clinical Trials			
	Omadacycline (N = 1073)	Linezolid (N = 689)	Moxifloxacin (N = 388)
Nausea[1]	14.9	8.7	5.4
Vomiting[1]	8.3	3.9	1.5
Diarrhea[2]	2.4	2.9	8.0
Transaminase Elevations Increased	4.3	4.4	5.2
Headache	2.9	3.0	1.3

Events of Nausea and Vomiting in Phase 3 CABP and ABSSSI Clinical Trials						
	CABP IV/Oral		ABSSSI IV/Oral		ABSSSI Oral-Only	
	IV	Oral	IV	Oral	Oral (D1 thru D2)	Oral (D3 thru EOT)
Nausea[1]	0.5	2.4	4.3	9.1	25.2	4.1
Vomiting	1.8	1.0	1.2	4.5	12.5	4.1

[1] Nearly all events of nausea and vomiting were mild or moderate in severity, resolved, and were not treatment limiting. Only 4 patients (0.4%) discontinued OMC treatment for nausea or vomiting.

[2] Diarrhea occurred in 2.4% of OMC patients and no cases of *C. difficile* infection were reported in OMC patients

PARATEK

Oral Bioavailability Results in High Omadacycline Concentrations in Urine

Supports Development for a UTI Indication

Day 1



Day 5



PARATEK

Phase 2 UTI Program Underway

Adaptive Dosing Designs Employed in Cystitis and Acute Pyelonephritis Studies



(1) Design and comparator subject to FDA discussions prior to initiation

PARATEK

Hospital Launch: Narrow Spectrum or IV-Only Antibiotic Launches

Omadacycline Will Be Competitive with the Best of These Launches



Source: IMS NSP data

Key Omadacycline launch attributes

- 1st new monotherapy for CABP in over a decade
- 2 indications at launch
- Once daily dosing
- Both an IV and Oral formulation

PARATEK

Community Promotion 2+ Years Post-Launch Expands The Market

Omadacycline Has the Potential to Realize This Opportunity



Source: IMS NSP data

PARATEK